References
- AmsterdamEAWengerNKBrindisRG2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesCirculation2014130252354239425249586
- JarvisBSimpsonKClopidogrel: a review of its use in the prevention of atherothrombosisDrugs200060234737710983738
- VeldersMAAbtanJAngiolilloDJSafety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary interventionHeart2016102861762526848185
- BurgerWChemnitiusJMKneisslGDRuckerGLow-dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta-analysisJ Intern Med2005257539941415836656
- TerpeningCAn appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular eventsJ Am Board Fam Med2009221515619124633
- ZhangQWangCZhengMAspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysisCerebrovasc Dis2015391132225547900
- DeharoPQuiliciJBonnetGFixed-dose aspirin-clopidogrel combination enhances compliance to aspirin after acute coronary syndromeInt J Cardiol20141721e1e224438924
- WertheimerAIThe economics of polypharmacology: fixed dose combinations and drug cocktailsCurr Med Chem201320131635163823410163
- CaplainHDonatFGaudCNecciariJPharmacokinetics of clopidogrelSemin Thromb Hemost199925Suppl 2252810440419
- Ministry of Food and Drug SafetyKorea Good Clinical Practice GuidelineChungcheongbuk-do, South KoreaMFDS2011 Korean
- BenedekIHJoshiASPieniaszekHJKingSYKornhauserDMVariability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteersJ Clin Pharmacol19953512118111868750369
- US Food and Drug AdministrationGuidance for Industry: Statistical Approaches to Establishing BioequivalenceSilver Springs, MDFDA2001
- ZhangHLauWCHollenbergPFFormation of the thiol conjugates and active metabolite of clopidogrel by human liver microsomesMol Pharmacol201282230230922584220
- DubovskaDPiotrovskijVKGajdosMKrivosikovaZSpustovaVTrnovecTPharmacokinetics of acetylsalicylic acid and its metabolites at low doses: a compartmental modelingMethods Find Exp Clin Pharmacol199517167777623523
- BaeSKSeoKAJungEJDetermination of acetylsalicylic acid and its major metabolite, salicylic acid, in human plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study of Astrix in Korean healthy volunteersBiomed Chromatogr200822659059518254152
- JungJAKimTEKimJRThe pharmacokinetics and safety of a fixed-dose combination of acetylsalicylic acid and clopidogrel compared with the concurrent administration of acetylsalicylic acid and clopidogrel in healthy subjects: a randomized, open-label, 2-sequence, 2-period, single-dose crossover studyClin Ther201335798599423870608
- TangMMukundanMYangJAntiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcoholJ Pharmacol Exp Ther200631931467147616943252
- SwigerKJYousufOBlidenKPTantryUSGurbelPACigarette smoking and clopidogrel interactionCurr Cardiol Rep201315536123591705
- HolmesMVPerelPShahTHingoraniADCasasJPCYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysisJAMA2011306242704271422203539
- XheliliEEichelbergerBKoppCWKoppensteinerRPanzerSGremmelTThe antiplatelet effect of clopidogrel decreases with patient ageAngiology Epub292016
- MareeAOFitzgeraldDJVariable platelet response to aspirin and clopidogrel in atherothrombotic diseaseCirculation2007115162196220717452618